Gerald Moncayo

Gerald Moncayo

Auto-generated profile, based on publicly available information

Gerald Moncayo

Biomedical Research Department, Friedrich Miescher Institute for Biomedical Research, Switzerland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Cellular Signalling
Verified
Journal Article
Closed access
MGMichal Grzmil
Michal Grzmil
JSJan Seebacher
Jan Seebacher
DHDaniel Hess
Daniel Hess
MBMartin Behe
Martin Behe
Roger SchibliRoger Schibli
Roger Schibli
BHBrian A. Hemmings
Brian A. Hemmings

5 September 2024 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
AKAlexia Kieffer
Alexia Kieffer
MBMatthieu Beuvelet
Matthieu Beuvelet
GMGerald Moncayo
Gerald Moncayo
MCMersha Chetty
Mersha Chetty
ASAditya Sardesai
Aditya Sardesai
RHRichard Hudson
Richard Hudson
Introduction Respiratory syncytial virus (RSV) leads to significant morbidity in newborn infants in the United Kingdom (UK). Nirsevimab, a long-acting monoclonal antibody, received approval from the European Medicines Agency and has been licensed by the Medicines and Healthcare products Regulatory Agency for preventing RSV lower respiratory tract disease (LRTD) in neonates and infants during their first RSV season. The objective of this study was to assess the potential impact of nirsevimab on RSV-associated LRTDs, related costs, and loss of quality-adjusted life years (QALYs) in infants experiencing their first RSV season. Methods The impact of administering nirsevimab across all infant populations compared to palivizumab in the high-risk palivizumab-eligible population was assessed via a static decision-analytic model specified for a UK birth cohort experiencing their first RSV season. The RSV-related health events of interest included primary care (PC), accident and emergency (A&E) visits, hospitalizations [including hospitalizations alone and those resulting in intensive care unit (ICU) admissions], recurrent wheezing in infants who were previously hospitalized, and all-cause LRTD hospitalizations. Results Under the current standard of practice (SoP), RSV was estimated to result in 329,425 RSV LRTDs annually, including 24,381 hospitalizations and ICU admissions, representing £117.8 million (2024 GBP) in costs. Comparatively, universal immunization of all infants with nirsevimab could avoid 198,886 RSV LRTDs, including 16,657 hospitalizations and ICU admissions, resulting in savings of £77.2 million in RSV treatment costs. Considering the impact on all-cause LRTD of a universal immunization strategy, nirsevimab could be valued between £243 and £274, assuming willingness-to-pay (WTP) thresholds of £20,000 and £30,000 per QALY saved, respectively. Conclusions This analysis demonstrated that the health and economic burden of RSV would be substantially reduced in all infants experiencing their first RSV season in the UK (including term, preterm, and palivizumab-eligible infants) as a result of a universal immunization strategy with nirsevimab.

10 June 2010
Verified
Dataset
Closed access
BHBrian Hemmings
Brian Hemmings
GXGongda Xue
Gongda Xue
GMGerald Moncayo
Gerald Moncayo
This manuscript sheds new light on the changes in microRNA abundance following epidermal growth factor receptor (EGFR) stimulation by EGF, connecting receptor tyrosine kinase (RTK) activation to altered transcriptional regulation. In this manuscript, the authors have quantified microRNA abundance in cells stimulated with EGF for different periods of time. Interestingly, they see 'waves' of microRNA changes that mimic previous...

1 April 2011
Verified
Dataset
Closed access
BHBrian Hemmings
Brian Hemmings
GMGerald Moncayo
Gerald Moncayo
This is an interesting methodological paper that shows the tumour suppressor role of the phosphatase PTPN12 in triple negative breast cancer (TNBC). Here, the authors find, using a small hairpin (sh)RNA genetic screen of kinases and phosphatases, that PTPN12 potently suppresses proliferation and hTert and T-antigen transformation of mammary cells in vitro. They then confirm the role in a 3D acinar formation model of MCF10A cells and in vivo through use of inducible shRNAs. They also find clinical relevance, since PTPN12 is often found absent in TNBCs and invasive breast cancers. As previously shown, PTPN12 is found mutated in several breast cancer cells {1}, some of which are shown to act as dominant negative. They also confirm, through bimolecular fluorescence complementation (BiFC), that PTPN12 interacts with platelet-derived growth factor receptor (PDGFR), human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) and regulates their activation. In addition, through correlation analysis, they show that it highly correlates with REST expression (p < 0.0001) and may be regulated through microRNA (miR)124. In line with this paper, PTPN12 may play a significant, vital role in various types of cancers, regulating progression and metastasis, as it may modulate receptor kinases and intracellular kinases such as SRC and focal adhesion kinase (FAK), and modulate RAS and Rho signalling {2-5}. Importantly, this paper re-emphasises the important role of phosphatases and the necessity of inhibiting various pathways to target effectively tumour growth.